Bioequivalence testing by statistical shape analysis

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 34, Issue 4, 2007, Pages 451-484

  Pereira, Luis Marcelo ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Bioequivalence; Information; KLIC; Kullback Leibler; Shape analysis

Indexed keywords

GENERIC DRUG;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CHI SQUARE TEST; CLINICAL PRACTICE; DECISION MAKING; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG INDUSTRY; DRUG RESEARCH; HUMAN; MATHEMATICAL MODEL; PRIORITY JOURNAL; SIMULATION; STATISTICAL ANALYSIS;

ALGORITHMS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CIPROFLOXACIN; COMPUTER SIMULATION; CONFIDENCE INTERVALS; DRUGS, GENERIC; HUMANS; MODELS, STATISTICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; THERAPEUTIC EQUIVALENCY;

EID: 34447128713     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-007-9055-3     Document Type: Article

References (100)

1. Drug price competition and patent term restoration act (1984) Health & Human Svc Dept, Rockville, MD
2. Bioavailability and Bioequivalence Requirements. Code of Federal Regulations Title21, vol.5 Part 320.24
3. Wagner JG (1971). Biopharmaceutics and relevant pharmacokinetics. Drug Intelligence Publications, Hamilton, Illinois
4. Sheiner LB (1992). Bioequivalence revisited. Statist Med 11: 1777-1788
5. Schuirmann DJ (1987). A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharm Biopharm 15: 657-680
6. Andersen S and Hauck WW (1990). Consideration of individual bioequivalence. J Pharmacok Biopharm 18: 259-273
7. Guidance on statistical procedures for Bioequivalence Studies using a Standard Two-Treatment Crossover Design (1992) FDA (Food and Drug Administration), Office of Generic Drugs, Rockville, MD
8. Guidance for industry: statistical approaches to establishing bioequivalence (2001) FDA (Food and Drug Administration), Center for Drug Evaluation and Research, Rockville, MD
9. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products - general considerations (2003) FDA (Food and Drug Administration), Center for Drug Evaluation and Research, Rockville, MD
10. Draft guidance: biostatistical methodology in clinical trials in applications for marketing authorization for medical products (1993) CPMP (Committee for Proprietary Medicinal Products)
11. Note for guidance on the investigation of bioavailability and bioequivalence (2001) CPMP (Committee for Proprietary Medicinal Products)
12. Conduct and analysis of bioavailability and bioequivalence studies - part a: oral dosage formulations used for systemic effects (1992) TPD (Therapeutic Products Directorate), Health Products and Food Branch, Minister of Health, Ottawa, Canada
13. Draft guidance for industry: clinical trial applications for comparative bioavailability studies for pharmaceuticals (2001) TPD - Therapeutic Products Directorate, Ottawa, Ontario
14. Japanese guidance on bioavailability and bioequivalence (2000) Eur J Drug Metab Pharmacok 25(1):28-31
15. Hauck WW and Anderson S (1992). Types of bioequivalence and related statistical considerations. Int J Clin Pharmacol Ther Toxicol 30: 181-187
16. Schall R and Luus HG (1993). On population and individual bioequivalence. Stat Med 12: 1109-1124
17. Gould AL (1997). Discussion of individual bioequivalence by M.L. Chen. J Biopharm Stat 7: 23-31
18. D'Argenio DA (1981). Optimal sampling times for pharmacokinetic experiments. J Pharm Biopharm 9: 739-756
19. Kong FH and Gonin R (1999). Optimal sampling times in bioequivalence tests. J Biopharm Stat 10(1): 31-44
20. Choi L, Caffo B, Rohde C (2004) Optimal sampling times in bioequivalence studies using a simulated annealing algorithm. Johns Hopkins University, Dept. of Biostatistics Working Papers, Paper 59
21. Smith BP (2005). It's time. AAPS J 7(3): E655-E658
22. Berger RL and Hsu JC (1996). Bioequivalence trials, intersection-union tests and equivalence confidence sets. Stat Sci 11(4): 283-319
23. max for absorption rates in investigations of bioequivalence. Int J Clin Pharmacol Ther Toxicol 29: 394-399
24. max/AUC useful for bioequivalence testing?. J Pharm Sci 86: 1504-1505
25. Holder DJ and Hsuan F (1993). Moment-based criteria for determining bioequivalence. Biometrika 80: 835-846
26. Hauck WW, Bois FY, Hyslop T, Gee L and Anderson S (1997). A parametric approach to population bioequivalence. Stat Med 16: 441-454
27. Mauger DT and Chinchilli VM (2000). An alternative index for assessing profile similarity in bioequivalence trials. Stat Med 19: 2855-2866
28. Chow SC and Tse SK (1990). Outlier detection in bioavailability/ bioequivalence studies. Stat Med 9: 549-558
29. Liu JP and Weng CS (1991). Detection of outlying data in bioavailability/bioequivalence studies. Stat Med 10: 1375-1389
30. Janssen A (2000). Nonparametric bioequivalence tests for statistical functionals and their efficient power functions. Stat Decis 18: 49-78
31. Wellek S (2000). Bayesian construction of an improved parametric test for probability-based individual bioequivalence. Biom J 42: 1039-1052
32. Freitag G, Czado C, Munk A (2006) A nonparametric test for similarity of marginals - with applications to the assessment of population bioequivalence. J Stat Plan Infer (in print)
33. Bristol DR (1999). Clinical equivalence. J Biopharm Stat 9(4): 549-561
34. Senn S (2001). Statistical issues in bioequivalence. Stat Med 20: 2785-2799
35. Hsuan F (2000). Some statistical considerations on the FDA draft guidance for individual bioequivalence. Stat Med 19: 2879-2884
36. Rescigno A (1992). Bioequivalence. Pharm Res 9(7): 925-928
37. Chinchilli VM and Elswick RK (1997). The multivariate assessment of bioequivalence. J Biopharm Stat 7(1): 113-123
38. Liao JJ (2005). Comparing the concentration curves directly in a pharmacokinetics, bioavailability/bioequivalence study. Stat Med 24(6): 883-891
39. Meredith P (2003). Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther 25(11): 2875-2890
40. APhA - American Pharmaceutical Association (2000) Substitution of Critical Dose Drugs: Issues, Analysis, and Decision Making. www.pharmacist.com/ pdf/critical_dose.pdf (accessed 2006 March 18)
41. Henderson JD and Esham RH (2001). Generic substitution: issues for problematic drugs. South Med J 94(1): 16-21
42. D'Arcy WT (1917) On growth and form. Cambridge University Press
43. Kendall DG (1984). Shape manifolds, Procrustean metrics and complex projective spaces. Bull London Math Soc 16: 81-121
44. Kendall DG (1988). Applied probability - past, present and future : a celebration of applied probability. J Appl Probab 25A: 25-30
45. Kendall DG (1989). A survey of the statistical theory of shape. Stat Sci 4(2): 87-120
46. Dryden IL, Mardia KV (1998) Statistical shape analysis. John Wiley & Son
47. Kendall DG, Barden D, Carne TK and Le H (1999). Shape and shape theory. Wiley, Chischester
48. Slice DE, Bookstein FL, Marcus LF, Rohlf FJ (1996) Appendix I: a glossary for geometric morphometrics. In: Marcus LF, Corti M, Loy A, Naylor GJP, Slice DE (eds) Advances in morphometrics, pp 531-551. Plenum Press, New York and London. (Revised in 1998 by F. James Rohlf in http://life.bio.sunysb.edu/morph/ glossary/gloss1.html)
49. Bookstein FL (1997). Landmark methods for forms without landmarks: localizing group differences in outline shape. Med Image Anal 1(3): 225-244
50. Bookstein FL (1991). Morphometric tools for landmark data: geometry and biology. Cambridge University Press, Cambridge
51. Stegmann MB, Gomez DD, A brief introduction to statistical shape analysis" Technical Report, March p.1-15, Informatics and Mathematical Modelling, Technical University of Denmark, DTU (2002).
52. Hotelling H (1933). Analysis of complex statistical variables into principal components. J Educ Psychol 24: 417-441
53. Cootes TF, Taylor CJ, Cooper DH and Graham J (1995). Active shape models: their training and application. Comp Vis Image Underst 61(1): 38-59
54. Duta N, Jain AK, Dubuisson-Jolly M-P (1999) Learning 2D shape models. in Proc. Conf. on Computer Vision and Pattern Recognition, 2:8-14
55. Kullback S (1959). Information theory and statistics. Wiley, NY
56. Small CG (1996). The statistical theory of shape. Springer Series in Statistics, Springer-Verlag, New York
57. Kullback S and Leibler RA (1951). On information and sufficiency. Ann Math Stat 22: 79-86
58. Akaike H (1974). A new look at the statistical model identification. IEEE Trans Automatic Control AC-19: 716-723
59. Schwarz G (1978). Estimating the dimension of a model. Ann Stat 6: 461-464
60. Hannan EJ and Quinn BG (1979). The determination of the order of an autoregression. J Royal Statist Soc Series B 41: 190-195
61. Fisher RA (1925). Statistical methods for research workers. Oliver and Boyd, London
62. Edwards AWF, Likelihood (1992) The John Hopkins University Press, Baltimore, MD
63. Jeffreys H (1961). Theory of Probability. Clarendon Press, Oxford
64. Hacking I (1965) Logic of statistical inference. Cambridge University Press
65. Särndal C-E (1970). A class of explicata for 'information' and 'weight of evidence'. Rev Int Stat Inst 38: 223-235
66. Fisher RA (1950). The logic of inductive inference. J Roy Stat Soc 98: 39-54
67. Pereira LM (1995) System analysis methods for drug absorption modeling: theory and applications. PhD Thesis, The University of Iowa, Iowa City, USA
68. Cover TM and Thomas JA (1991). Elements of information theory. John Wiley and Sons, NY
69. Steinijans VW, Sauter R and Diletti E (1995). Shape analysis in single- and multiple-dose studies of modified release products. In: Blume, HH and Midha, KK (eds) Bio-International 2 - bioavailability, bioequivalence and pharmacokinetic studies, pp. Medpharm GmbH Scientific Publishers, Stuttgart Germany
70. Dragalin V, Fedorov V, Patterson S and Jones B (2003). Kullback-Leibler divergence for evaluating bioequivalence. Stat Med 22: 913-930
71. Bristol DR (1999). Clinical equivalence. J Biopharm Stat 9(4): 549-561
72. Garrett AD (2003). Therapeutic equivalence: fallacies and falsification. Stat Med 22: 741-762
73. Archambeau C, Verleysen M (2003) Fully nonparametric probability density function estimation with finite Gaussian mixture models. ICAPR'2003 Proceedings - 5th International Conference on Advances in Pattern Recognition, Calcutta, 81-4, Allied Publishers Pvt. Ltd., New Delhi, India
74. th International Conference on Acoustics, Speech, and Signal Processing (ICASSP), Hong Kong
75. Willett RM, Nowak R (2002) Multiresolution nonparametric intensity and density estimation. IEEE International Conference on Acoustics, Speech and Signal Processing (ICASSP), Orlando FL
76. Scott DW (1992). Multivariate density estimation, theory, practice and visualization. John Wiley & Sons, NY
77. Silverman BW (1986) Density estimation for statistics and data analysis. Chapman & Hall
78. Agresti A (2002) Categorical data analysis. Wiley Series in Probability and Statistics, John Wiley & Sons
79. 2 test of goodness of fit. Ann Math Stat 23: 315-345
80. Ben-Gal I, Morag G and Shmilivici A (2003). Context-based statistical process control: a monitoring procedure for state-dependent processes. Technometrics 45(4): 293-311
81. Holm S (1979). A simple sequentially rejective multiple test procedure. Scand J Stat 6: 65-70
82. Shaffer J (1986). Modified sequentially rejective multiple test procedures. J Am Stat 81: 826-831
83. D'Argenio DZ and Schumitzky A (1997). ADAPT II user's guide. Biomedical Simulations Resource. University of Southern California, Los Angeles
84. WinNonlin, version 5.1 (2005) Pharsight Corp., Cary, N.C.
85. Statistical Analysis System, SAS Institute Inc., Cary, N.C.
86. Nesseem DI, Taleb NFA, Abou-Basha L and Molokhia AM (2006). Randomized crossover studies of the bioequivalence of two commercially available ciprofloxacin after administration of a single oral dose in healthy volunteers. HIV AIDS Rev 5(1): 20-29
87. S-plus, version 6, Insight, Inc., Seattle, WA
88. Filliben JJ and Heckert A (2005). Dataplot for Windows 2000/XP, Statistical engineering division. National Institute of Standards and Technology, Gaithersburg MD
89. Gwet K (2001) Handbook of inter-rater reliability. STATAXIS Publishing Co.
90. Chinchilli VM and Esinhart (1996). Design and analysis of intrasubject variability in crossover experiments. Stat Med 15: 1619-1634
91. Chow SC and Tse SK (1990). Outlier detection in bioavailability/ bioequivalence studies. Stat Med 9: 549-558
92. McNally RJ, Iyer H and Mathew T (2002). Tests for individual and population bioequivalence based on generalized p-values. Stat Med 22(1): 31-53
93. Tsui KW and Weerahandi S (1989). Generalized p-values in significance testing of hypotheses in the presence of nuisance parameters. J Am Stat Assoc 84(406): 602-607
94. Berger J (2003). Could Fisher, Jeffreys and Neyman have agreed upon testing?. Stat Sci 18: 1-32
95. Blume J and Peipert JF (2003). What your statistician never told you about p-values. J Am Assoc Gynecol Laparosc 10(4): 439-444
96. Fisher RA (1959). Statistical methods and scientific inference. Oliver and Boyd, Edinburg
97. Neyman J (1961). Silver jubilee of my dispute with Fisher. J Oper Res Soc Jpn 3: 145-154
98. Hubbard R and Bayarri MJ (2003). Confusion over measures of evidence (p's) versus errors (α's) in classical statistical testing. Am Stat 57: 171-182
99. Goodman SN (1993). p values, hypothesis tests and likelihood: implications for epidemiology of a neglected historical debate. Am J Epidemiol 137: 485-496
100. Lehman EL (1993). The Fisher, Neyman-Person theories of testing hypotheses: one theory or two?. J Am Stat Assoc 88: 1242-1249